Home › Nerviano Medical Sciences And Servier Announce A Collaboration And License Agreement For A Novel Anticancer Drug
 

Keywords :   


Nerviano Medical Sciences And Servier Announce A Collaboration And License Agreement For A Novel Anticancer Drug

2013-07-30 09:00:00| drugdiscoveryonline News Articles

Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy, one of the leading oncology-focused, integrated discovery and development companies in Europe, and Servier, a leading research-based European pharmaceutical company recently announced a collaboration and worldwide license agreement to further develop and commercialize first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1

Tags: agreement medical license drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07Sensory analysis shows pork has 111 unique flavor nuances
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 19A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07'Floodgates open' for legal action against water firms
03.07Atlantic Tropical Weather Outlook
03.07Eastern North Pacific Tropical Weather Outlook
More »